| Nucleic acid therapeutics for hematologic malignancies--theoretical considerations. | |
| | |
MedLine Citation:
|
PMID: 17145934 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Our work is motivated by the belief that RNA targeted gene silencing agents can be developed into effective drugs for treating hematologic malignancies. In many experimental systems, antisense nucleic acids of various composition, including antisense oligodeoxynucleotides (AS ODNs) and short interfering RNA (siRNA), have been shown to perturb gene expression in a sequence specific manner. Nevertheless, our clinical experience, and those of others, have led us to conclude that the antisense nucleic acids (ASNAs) we, and others, employ need to be optimized with regard to intracellular delivery, targeting, chemical composition, and efficiency of mRNA destruction. We have hypothesized that addressing these critical issues will lead to the development of practical and effective nucleic acid drugs. An overview of our recent work which seeks to addresses these core issues is contained within this review. |
| | |
Authors:
|
Joanna B Opalinska; Anna Kalota; Jyoti Chattopadhyaya; Masad Damha; Alan M Gewirtz |
Related Documents
:
|
10865154 - Development of probes to differentiate porcine circovirus types 1 and 2 in vitro by in ... 19886694 - Efficient nucleic acid detection by templated reductive quencher release. 6197074 - Free radical metabolism of hydralazine. binding and degradation of nucleic acids. 9759484 - Modified oligonucleotides: synthesis and strategy for users. 6509024 - Effect of surface composition on triolein hydrolysis in phospholipid vesicles and micro... 2248974 - Phosphatidylcholine metabolism for energy production in sea urchin spermatozoa. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1082 ISSN: 0077-8923 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2006 Oct |
Date Detail:
|
Created Date: 2006-12-05 Completed Date: 2007-03-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 124-36 Citation Subset: IM |
Affiliation:
|
Pommeranian Medical Academy, 71245 Szczecin, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Hematologic Neoplasms
/
drug therapy* Humans Nucleic Acids / administration & dosage, therapeutic use* Oligonucleotides, Antisense / administration & dosage, chemistry, therapeutic use RNA, Small Interfering / administration & dosage, chemistry, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Nucleic Acids; 0/Oligonucleotides, Antisense; 0/RNA, Small Interfering |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modification of the pig CFTR gene mediated by small fragment homologous replacement.
Next Document: CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.